Gordon Saul

Executive Director, Biodesign
Consulting Professor, Bioengineering
Stanford University
Stanford, CA

Gordon has over 20 years startup and business development experience in the medical device and pharmaceutical areas. Prior to joining Stanford’s Program in Biodesign, Gordon was an Executive-in-Residence at InterWest Partners, a leading Silicon Valley venture capital firm. At InterWest, Gordon served as a founding or interim executive in over a dozen medical device and drug companies in the InterWest portfolio.

Prior to joining InterWest, he was a co-founder, board member and senior vice president of business development and marketing for PowderJect Pharmaceuticals, a publicly traded drug delivery company acquired by Chiron Corporation in 2003. Prior to PowderJect, he held business development roles at ALZA Corporation and Advanced Cardiovascular Systems, a division of Guidant Corp. He has also worked in Japan in the financial services industry and in management consulting for The Boston Consulting Group.

Gordon received an A.B. in engineering sciences from Dartmouth College and an M.B.A. from Stanford University.